InspireMD (NSPR) 10-Q 7 Aug 23 2023 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2023	Aug. 07, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-35731
Entity Registrant Name	InspireMD, Inc.
Entity Central Index Key	0001433607
Entity Tax Identification Number	26-2123838
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	4 Menorat Hamaor St.
Entity Address, City or Town	Tel Aviv
Entity Address, Country	IL
Entity Address, Postal Zip Code	6744832
City Area Code	888
Local Phone Number	776-6204
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NSPR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		21,195,103

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands		Jun. 30, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents		$ 11,545	$ 4,632
Short-term bank deposits		6,631	13,171
Marketable securities		28,817
Accounts receivable:
Trade, net		1,470	1,034
Other		312	213
Prepaid expenses		56	655
Inventory		1,689	1,621
TOTAL CURRENT ASSETS		50,520	21,326
NON-CURRENT ASSETS:
Property, plant and equipment, net		873	917
Operating lease right of use assets		1,388	1,554
Fund in respect of employee rights upon retirement		857	856
TOTAL NON-CURRENT ASSETS		3,118	3,327
TOTAL ASSETS		53,638	24,653
Accounts payable and accruals:
Trade		768	659
Other		4,061	4,411
TOTAL CURRENT LIABILITIES		4,829	5,070
LONG-TERM LIABILITIES-
Operating lease liabilities		970	1,195
Liability for employees’ rights upon retirement		1,026	995
TOTAL LONG-TERM LIABILITIES		1,996	2,190
COMMITMENTS AND CONTINGENT LIABILITIES
TOTAL LIABILITIES		6,825	7,260
EQUITY:
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at June 30, 2023 and December 31, 2022; 21,192,204 and 8,330,918 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively		2	1
Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at June 30, 2023 and December 31, 2022; 1,718 shares issued and outstanding at June 30, 2023 and December 31 2022, respectively	[1]
Additional paid-in capital		257,729	218,977
Accumulated deficit		(210,918)	(201,585)
Total equity		46,813	17,393
Total liabilities and equity		$ 53,638	$ 24,653
[1]Represents an amount less than $1 thousand

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	21,192,204	8,330,918
Common stock, shares outstanding	21,192,204	8,330,918
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,172,000	1,172,000
Preferred stock, shares outstanding	1,718	1,718
Preferred stock, shares issued	1,718	1,718

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
REVENUES	$ 1,649	$ 1,531	$ 2,888	$ 2,714
COST OF REVENUES	1,158	1,100	2,024	2,161
GROSS PROFIT	491	431	864	553
OPERATING EXPENSES:
Research and development	1,993	2,056	3,836	3,736
Selling and marketing	892	986	1,680	1,732
General and administrative	2,921	2,070	5,044	4,252
Total operating expenses	5,806	5,112	10,560	9,720
LOSS FROM OPERATIONS	(5,315)	(4,681)	(9,696)	(9,167)
FINANCIAL INCOME, net:	238	45	363	50
NET LOSS	$ (5,077)	$ (4,636)	$ (9,333)	$ (9,117)
NET LOSS PER SHARE - basic	$ (0.24)	$ (0.59)	$ (0.64)	$ (1.17)
NET LOSS PER SHARE - diluted	$ (0.24)	$ (0.59)	$ (0.64)	$ (1.17)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic	21,074,187	7,807,795	14,619,622	7,806,030
EIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - diluted	21,074,187	7,807,795	14,619,622	7,806,030

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($)	Common Stock [Member]		Preferred Stock [Member] Series C Convertible Preferred Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 1,000			[1]	$ 216,625,000	$ (183,094,000)	$ 33,532,000
Balance, shares at Dec. 31, 2021	8,296,256		1,718
Net loss						(9,117,000)	(9,117,000)
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures of 4,563 shares		[1]			1,327,000		1,327,000
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures, shares	26,944
Balance at Jun. 30, 2022	$ 1,000			[1]	217,952,000	(192,211,000)	25,742,000
Balance, shares at Jun. 30, 2022	8,323,200		1,718
Balance at Mar. 31, 2022	$ 1,000			[2]	217,278,000	(187,575,000)	29,704,000
Balance, shares at Mar. 31, 2022	8,317,876		1,718
Net loss						(4,636,000)	(4,636,000)
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award		[2]			674,000		674,000
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, shares	5,324
Balance at Jun. 30, 2022	$ 1,000			[1]	217,952,000	(192,211,000)	25,742,000
Balance, shares at Jun. 30, 2022	8,323,200		1,718
Balance at Dec. 31, 2022	$ 1,000			[3]	218,977,000	(201,585,000)	17,393,000
Balance, shares at Dec. 31, 2022	8,330,918		1,718
Net loss						(9,333,000)	(9,333,000)
Share-based compensation related to restricted stock, restricted stock units and stock options award, net of forfeitures, shares	2,595,016
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award		[3]			1,219,000		1,219,000
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs	$ 1,000				37,533,000		37,534,000
Issuance of common shares and pre-funded warrants, warrants, net of $4,365 issuance costs, shares	10,266,270
Balance at Jun. 30, 2023	$ 2,000			[3]	257,729,000	(210,918,000)	46,813,000
Balance, shares at Jun. 30, 2023	21,192,204		1,718
Balance at Mar. 31, 2023	$ 1,000			[4]	219,266,000	(205,841,000)	13,426,000
Balance, shares at Mar. 31, 2023	8,326,648		1,718
Net loss						(5,077,000)	(5,077,000)
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award		[4]			930,000		930,000
Share-based compensation related to stock, restricted stock, restricted stock units and stock options award, shares	2,599,286
Issuance of common shares, pre-funded warrants and warrants, net of $4,635 issuance costs	$ 1,000				37,533,000		37,534,000
Issuance of common shares and pre-funded warrants, warrants, net of $4,365 issuance costs, shares	10,266,270
Balance at Jun. 30, 2023	$ 2,000			[3]	$ 257,729,000	$ (210,918,000)	$ 46,813,000
Balance, shares at Jun. 30, 2023	21,192,204		1,718
[1]Represents an amount less than $1 thousand[2]Represents an amount less than $1 thousand[3]Represents an amount less than $1 thousand[4]Represents an amount less than $1 thousand

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Statement of Stockholders' Equity [Abstract]
Shares, restricted stock award, forfeited	4,270	4,563
Payments of stock issuance costs	$ 4,635

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,333)	$ (9,117)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	113	84
Gain from sale of property, plant and equipment	(8)
Loss on amounts funded in respect of employee rights upon retirement	42	103
Changes in fair value of marketable securities	21
Change in liability for employees’ rights upon retirement	31	(90)
Other financial expenses	23	132
Change in operating right of use asset and leasing liability	(60)	(63)
Share-based compensation expenses	1,219	1,327
Decrease (increase) in interest receivable on short term deposits	40	(42)
Changes in operating asset and liability items:
Decrease in prepaid expenses	599	338
Decrease (increase) in trade receivables	(436)	41
Increase in other receivables	(99)	(6)
Increase in inventory	(68)	(311)
Increase in trade payables	109	234
Increase (decrease) in other payables	(349)	127
Net cash used in operating activities	(8,156)	(7,243)
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in short-term bank deposits	(5,500)	(10,000)
Purchase of property, plant and equipment	(70)	(152)
Proceeds from sale of property, plant and equipment	9
Investments in marketable securities	(28,838)
Withdrawal from short-term bank deposits	12,000	12,000
Amounts funded in respect of employee rights upon retirement	(43)	(47)
Net cash provided by (used in) investing activities	(22,442)	1,801
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance costs of At The Market offering		(37)
Proceeds from issuance of shares and warrants net of $4,635 issuance costs,	37,534
Net cash provided by financing activities	37,534	(37)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(23)	(132)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	6,913	(5,611)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD	4,632	12,004
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	11,545	6,393
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Acquisition of right-of-use assets by means of lease liabilities		$ 835

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited)(Parenthetical) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Statement of Cash Flows [Abstract]
Payments of stock issuance costs	$ 4,635	$ 4,635

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS a. General InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company’s MGuard™ Prime™ embolic protection system (“MGuard Prime EPS”) was marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions, or bypass surgery. MGuard Prime EPS combines MicroNet with a bare-metal cobalt-chromium based stent. MGuard Prime EPS received CE mark approval in the European Union in October 2010 for improving luminal diameter and providing embolic protection. Over the past years, there has been a shift in industry preferences away from bare-metal stents, such as MGuard Prime EPS in ST-Elevation Myocardial Infarction (“STEMI”) patients. As a result of declining sales of the MGuard Prime EPS, which the Company believes is largely driven by the predominant industry preferences favoring drug-eluting, or drug-coated, stents, during the second quarter of 2022, the Company ceased sales of the Company’s MGuard Prime EPS following a phase out period. The Company markets its products through distributors in international markets, mainly in Europe. As of the date of issuance of the consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. Therefore, in order to fund the Company’s operations until such time that the Company can generate substantial revenues, the Company may need to raise additional funds. b. Failure to satisfy regulatory requirements of the new European Medical Device Regulation could prevent the Company from marketing CGuard EPS in countries requiring the CE Mark. For the European Union nations, medical devices must obtain a CE mark before they may be placed on the market. In order to obtain and maintain the CE mark, the Company must Company with EU law on medical devices, which, until May 26, 2021 was governed by the MDD, by presenting comprehensive technical files for the Company’s products demonstrating safety and efficacy of the product to be placed on the market and passing initial and annual quality management system audit as per ISO 13485 standard by a European Notified Body. The company has obtained ISO 13485 quality system certification and CGuard EPS that the Company currently distribute into the European Union, displays the required CE mark. In order to maintain certification, the Company is required to pass an annual surveillance audit conducted by Notified Body auditors. The European Union replaced the MDD with the new MDR regulations. The MDR entered into force after a transitional period of three years and a one year extension of that transition period due to the COVID-19 pandemic on May 26, 2021 and which changes several aspects of the regulatory framework in the European Union. Manufacturers had the duration of the transition period to update their technical documentation and processes to meet the new requirements in order to obtain a CE Mark. In the Company’s specific case, the Company’s CE mark for CGuard EPS under the MDD expired on November 12, 2022, and the Company is in the final stages of technical documentation review by the Notified Body auditor to meet the MDR requirements for recertification. In the meantime, on February 14, 2023, the Company received a derogation per Article 97 paragraph 1 of Regulation 2017/745 from the Agency for Medicines and Health Products (FAMHP) allowing the Company to continue marketing CGuard EPS in the EU until August 15, 2023, subject to certain procedural requirements. Subsequently, on March 20, 2023 Regulation (EU) 2023/607 was published allowing the Company to continue marketing CGuard EPS in EU countries under the MDD directive until December 31, 2027. As a result of the foregoing, the Company may market and sell CGuard EPS in the EU and certain other jurisdictions subject to certain procedural requirements while the Company’s MDR CE recertification is pending. c. Risks Related to the Geopolitical and Military Tensions Between Russia and Ukraine in Europe In February 2022, Russia launched a military invasion into Ukraine. The Company derived approximately 12.1% of total sales in Russia and Belarus in 2022 while during the six and three months ended June 30, 2023, the Company’s sales to Russia and Belarus were 10.0% and 11.6%, compared to 6.8% and 10.9% in the six and three months ended June 30, 2022, respectively. The escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble could negatively impact the Company’s operations, sales, and future growth prospects in that region. As a result of the crisis in Ukraine, the United States and the EU have implemented sanctions against certain Russian individuals and entities and have made it more difficult for the Company to collect on outstanding accounts receivable from customers in this region. The Company’s global operations expose the Company to risks that could adversely affect the Company’s business, financial condition, results of operations, cash flows or the market price of the Company’s securities, including the potential for increased tensions between the United States and Russia resulting from the current situation involving Russia and Ukraine, tariffs, economic sanctions and import-export restrictions imposed by either nation, and retaliatory actions by the other nation, as well as the potential negative impact on the Company’s business and sales in Russia and Belarus. Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S. government against certain companies and individuals may hinder the Company’s ability to conduct business with potential or existing customers and vendors in these countries. The U.S. government has imposed sanctions through several executive orders restricting U.S. companies from conducting business with specified Russian individuals and companies. While the Company believes that the executive orders currently do not preclude the Company from conducting business with the Company’s current customers or vendors in Russia and Belarus, the sanctions imposed by the U.S. government may be expanded in the future to restrict the Company from engaging with them. If the Company is unable to conduct business with new or existing customers or vendors or pursue business opportunities in Russia or Belarus, the Company’s business, including revenue, profitability and cash flows, and operations could be adversely affected. The Company cannot provide assurance that current sanctions or potential future changes in sanctions will not have a material impact on the Company’s operations in Russia and Belarus or on the Company’s financial results.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 2 - BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements for the year ended December 31, 2022. In the opinion of the company, all adjustments considered necessary for a fair statement of the results of the interim periods reported herein have been included (consisting only of normal recurring adjustments). These consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022, as found in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 30, 2023. The results of operations for the three and six months ended June 30, 2023, are not necessarily indicative of results that could be expected for the entire fiscal year. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of June 30, 2023, cash and cash equivalents consisted of cash, short-term deposits (up to three months from the date of deposit) and money market funds. As of December 31, 2022, this balance consisted solely of cash. Marketable securities Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.

NEW ACCOUNTING PRONOUNCEMENT

NEW ACCOUNTING PRONOUNCEMENT	6 Months Ended
	Jun. 30, 2023
Accounting Changes and Error Corrections [Abstract]
NEW ACCOUNTING PRONOUNCEMENT	NOTE 3 - NEW ACCOUNTING PRONOUNCEMENT Recently adopted accounting pronouncement In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies had an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company met the definition of an SRC and adopted the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company adopted the provisions of this update as of January 1, 2023 with no material impact on its consolidated financial statements. Recently issued accounting pronouncement, not yet adopted In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40).” This guidance simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of the adoption of ASU 2020-06 on the Company’s consolidated financial statements.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 4 – FAIR VALUE MEASUREMENTS Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS Total Level 1 Level 2 Level 3 As of June 30, 2023 Total Level 1 Level 2 Level 3 ($ in thousands) Assets: Cash equivalents- Money market funds $ 3,598 $ 3,598 $ - $ - Cash equivalents $ 3,598 $ 3,598 $ - $ - Marketable securities- U.S government bonds $ 28,817 $ - $ 28,817 $ - Marketable securities $ 28,817 $ - $ 28,817 $ - The Company’s debt securities are classified within Level 2 because it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs to determine their fair value. The cost of marketable securities as of June 30, 2023 is $ 28,838

MARKETABLE SECURITIES

MARKETABLE SECURITIES	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
MARKETABLE SECURITIES	NOTE 5 - MARKETABLE SECURITIES The following table sets forth the Company’s marketable securities for the indicated period: SCHEDULE OF MARKETABLE SECURITIES June 30, December 31, 2023 2022 ($ in thousands) U.S government bonds $ 28,817 $ - Marketable securities $ 28,817 $ - The following table summarizes the fair value of the Company’s marketable securities classified by maturity as of June 30, 2023, and December 31, 2022: SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY June 30, December 31, 2023 2022 ($ in thousands) Amounts maturing within one year $ 17,429 $ - Amounts maturing after one year through two years 11,388 - $ 28,817 $ - The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the six months period ended June 30, 2023: SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES Six months ended 2023 ($ in thousands) Balance at beginning of the period $ - Additions 28,838 Sale or maturity - Changes in fair value during the period (21 ) Balance at end of the period 28,817 Balance at end of the period 28,817

EQUITY

EQUITY	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
EQUITY	NOTE 6 - EQUITY a. Private Placement On May 12, 2023, the Company entered into a securities purchase agreement (the “Purchase Agreement”) pursuant to which the Company agreed to sell and issue in a private placement (the “Private Placement Offering) an aggregate of 10,266,270 15,561,894 51,656,328 12,914,086 12,914,078 12,914,086 12,914,078 1.6327 1.6326 Aggregate gross proceeds to the Company in respect of the Private Placement Offering were $ 42.2 4.6 71.4 The Pre-Funded Warrants are immediately exercisable at an exercise price of $ 0.0001 1.3827 As of June 30, 2023, there are 15,561,894 Pursuant to the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s Series C Preferred Stock, the conversion price of the outstanding shares of the Series C Preferred Stock was reduced to $ 1.3827 5,668 1,718 As of June 30, 2023, there were 1,718 7,952 b. As of June 30, 2023, the Company has outstanding warrants to purchase an aggregate of 53,449,832 SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK Number of Exercise price Series E Warrants 198,159 $ 27.000 0 Series F Warrants 433,878 $ 7.4250 Series G Warrants 1,092,344 $ 10.230 0 Series H Warrants 12,914,086 $ 1.3827 Series I Warrants 12,914,078 $ 1.3827 Series J Warrants 12,914,086 $ 1.3827 Series K Warrants 12,914,078 $ 1.3827 Underwriter Warrants 17,966 $ 7.4250 Other warrants 51,157 225 and above Total Warrants 53,449,832 $ As of June 30, 2023, the Company had 155,000,000 0.0001 150,000,000 5,000,000 c. During the six months ended June 30, 2023, the Company granted 2,569,540 The fair value of the above restricted shares was approximately $ 4.52 d. During the six months ended June 30, 2023, the Company granted 1,045,150 The fair value of the above restricted share units was approximately $ 1,839 e. On January 6, 2023, the Company granted to a consultant options to purchase a total of 50,000 1.15 45,000 20,000 15,000 10,000 5,000 In calculating the fair value of the above options, the Company used the following assumptions: dividend yield of 0 5.125 6.5 124.58 125.61 3.65 3.68 The fair value of the above options, using the Black-Scholes option-pricing model, was approximately $ 50,658 On May 17, 2023, the Company granted to employees and directors options to purchase a total of 1,011,930 1.76 In calculating the fair value of the above options the Company used the following assumptions: dividend yield of 0 5.5 6.5 116.76 123.30 3.58 The fair value of the above options, using the Black-Scholes option-pricing model, was approximately $ 1.56 On May 17, 2023, the Company granted to consultants options to purchase a total of 575,000 1.76 In calculating the fair value of the above options the Company used the following assumptions: dividend yield of 0 5.5 6.5 116.76 123.30 3.58 The fair value of the above options, using the Black-Scholes option-pricing model, was approximately $ 885 f. Election to Receive Shares of Common Stock in lieu of Cash Compensation Beginning on January 1, 2023, non-employee directors may elect to receive all or a portion of their cash retainer amount in shares of the Company’s common stock under the 2021 Equity Incentive Plan. If a director makes that election, a stock award under the 2021 Equity Incentive Plan will be paid quarterly on the first day of each next quarter (“Issuance Dates”) and will become fully vested on the Issuance Dates. The stock award will be determined by dividing (x) the product of the cash retainer amount and percentage of the cash retainer amount elected to be taken in shares by (y) the “Fair Market Value” (as defined in the 2021 Equity Incentive Plan) of a share on the Issuance Dates. If a director’s service on the board terminates for any reasons prior to an Issuance Date, he/she will receive a pro rata portion of shares or cash based on the number of days served on the board during the relevant quarter. On April 1, 2023, the Company issued 29,746 55,000 22,875 32,125 12,648

RELATED PARTIES TRANSACTIONS

RELATED PARTIES TRANSACTIONS	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTIES TRANSACTIONS	NOTE 7 – RELATED PARTIES TRANSACTIONS During the six and three months ended June 30, 2022, a consulting company whose founder and CEO is a member of the company’s board of directors, provided certain marketing services in the amount of $ 8,776 2,500 no

NET LOSS PER SHARE

NET LOSS PER SHARE	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
NET LOSS PER SHARE	NOTE 8 - NET LOSS PER SHARE Basic and diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock, fully vested pre-funded warrants and fully vested restricted stock units outstanding during the period. The calculation of diluted net loss per share excludes potential share issuances of common stock upon the exercise of share options, warrants, and unvested restricted stocks, unvested restricted stock units and Series C preferred stock as the effect is anti-dilutive. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the Pre-funded Warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them. For the six and three-month periods ended June 30, 2023, we had weighted average Pre-funded Warrants of 3,954,956 and 7,866,452 , respectively, which were used in the computations of net loss per share for the six and three-month periods. The total number of shares of common stock related to outstanding options, warrants, unvested restricted stock, unvested restricted stock units and Series C Preferred Stock excluded from the calculations of diluted loss per share were 75,186,979 2,905,615 The total number of shares of common stock related to outstanding options, warrants, restricted stock, restricted stock units and Series C Preferred Stock excluded from the calculations of diluted loss per share were 3,010,707 547,792

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2023
Investments, All Other Investments [Abstract]
FINANCIAL INSTRUMENTS	NOTE 9 - FINANCIAL INSTRUMENTS a. Fair value of financial instruments The carrying amounts of financial instruments approximate their fair value either because these amounts are presented at fair value or due to the relatively short-term maturities of such instruments. b. As of June 30, 2023, and December 31, 2022, allowance for expected credit loss was immaterial.

INVENTORY

INVENTORY	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
INVENTORY	NOTE 10- INVENTORY SCHEDULE OF INVENTORIES June 30, December 31, 2023 2022 ($ in thousands) Finished goods $ 177 $ 179 Work in process 513 510 Raw materials and supplies 999 932 Total inventory $ 1,689 $ 1,621

ACCOUNTS PAYABLE AND ACCRUALS -

ACCOUNTS PAYABLE AND ACCRUALS - OTHER	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUALS - OTHER	NOTE 11 - ACCOUNTS PAYABLE AND ACCRUALS - OTHER SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER June 30, December 31, 2023 2022 ($ in thousands) Employees and employee institutions 1,263 1,853 Accrued vacation and recreation pay 303 197 Accrued expenses 742 554 Clinical trial accrual 1,214 1,258 Current Operating lease liabilities 418 419 Other 121 130 Accounts Payable and Accruals - Other 4,061 4,411

DISAGGREGATED REVENUE AND ENTIT

DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES	NOTE 12 - DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS Three months ended Six months ended 2023 2022 2023 2022 ($ in thousands) Germany $ 276 $ 426 $ 490 $ 675 Italy 338 229 605 473 Other 1,035 876 1,793 1,566 $ 1,649 $ 1,531 $ 2,888 $ 2,714 By product: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT Three months ended Six months ended 2023 2022 2023 2022 ($ in thousands) CGuard $ 1,649 $ 1,505 $ 2,888 $ 2,666 MGuard - 26 - 48 $ 1,649 $ 1,531 $ 2,888 $ 2,714 By principal customers: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS Three months ended Six months ended 2023 2022 2023 2022 Customer A 17 % 28 % 17 % 25 % Customer B 11 % 8 % 12 % 9 % All tangible long lived assets are located in Israel.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of June 30, 2023, cash and cash equivalents consisted of cash, short-term deposits (up to three months from the date of deposit) and money market funds. As of December 31, 2022, this balance consisted solely of cash.
Marketable securities	Marketable securities Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS	The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows: SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS Total Level 1 Level 2 Level 3 As of June 30, 2023 Total Level 1 Level 2 Level 3 ($ in thousands) Assets: Cash equivalents- Money market funds $ 3,598 $ 3,598 $ - $ - Cash equivalents $ 3,598 $ 3,598 $ - $ - Marketable securities- U.S government bonds $ 28,817 $ - $ 28,817 $ - Marketable securities $ 28,817 $ - $ 28,817 $ -

MARKETABLE SECURITIES (Tables)

MARKETABLE SECURITIES (Tables)	6 Months Ended
	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
SCHEDULE OF MARKETABLE SECURITIES	The following table sets forth the Company’s marketable securities for the indicated period: SCHEDULE OF MARKETABLE SECURITIES June 30, December 31, 2023 2022 ($ in thousands) U.S government bonds $ 28,817 $ - Marketable securities $ 28,817 $ -
SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY	The following table summarizes the fair value of the Company’s marketable securities classified by maturity as of June 30, 2023, and December 31, 2022: SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY June 30, December 31, 2023 2022 ($ in thousands) Amounts maturing within one year $ 17,429 $ - Amounts maturing after one year through two years 11,388 - $ 28,817 $ -
SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES	The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the six months period ended June 30, 2023: SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES Six months ended 2023 ($ in thousands) Balance at beginning of the period $ - Additions 28,838 Sale or maturity - Changes in fair value during the period (21 ) Balance at end of the period 28,817 Balance at end of the period 28,817

EQUITY (Tables)

EQUITY (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK	SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK Number of Exercise price Series E Warrants 198,159 $ 27.000 0 Series F Warrants 433,878 $ 7.4250 Series G Warrants 1,092,344 $ 10.230 0 Series H Warrants 12,914,086 $ 1.3827 Series I Warrants 12,914,078 $ 1.3827 Series J Warrants 12,914,086 $ 1.3827 Series K Warrants 12,914,078 $ 1.3827 Underwriter Warrants 17,966 $ 7.4250 Other warrants 51,157 225 and above Total Warrants 53,449,832 $

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	SCHEDULE OF INVENTORIES June 30, December 31, 2023 2022 ($ in thousands) Finished goods $ 177 $ 179 Work in process 513 510 Raw materials and supplies 999 932 Total inventory $ 1,689 $ 1,621

ACCOUNTS PAYABLE AND ACCRUALS_2

ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Tables)	6 Months Ended
	Jun. 30, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER	SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER June 30, December 31, 2023 2022 ($ in thousands) Employees and employee institutions 1,263 1,853 Accrued vacation and recreation pay 303 197 Accrued expenses 742 554 Clinical trial accrual 1,214 1,258 Current Operating lease liabilities 418 419 Other 121 130 Accounts Payable and Accruals - Other 4,061 4,411

DISAGGREGATED REVENUE AND ENT_2

DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS	Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS Three months ended Six months ended 2023 2022 2023 2022 ($ in thousands) Germany $ 276 $ 426 $ 490 $ 675 Italy 338 229 605 473 Other 1,035 876 1,793 1,566 $ 1,649 $ 1,531 $ 2,888 $ 2,714
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT	By product: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT Three months ended Six months ended 2023 2022 2023 2022 ($ in thousands) CGuard $ 1,649 $ 1,505 $ 2,888 $ 2,666 MGuard - 26 - 48 $ 1,649 $ 1,531 $ 2,888 $ 2,714
SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS	By principal customers: SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS Three months ended Six months ended 2023 2022 2023 2022 Customer A 17 % 28 % 17 % 25 % Customer B 11 % 8 % 12 % 9 %

SCHEDULE OF FINANCIAL ASSETS SU

SCHEDULE OF FINANCIAL ASSETS SUBJECT TO FAIR VALUE MEASUREMENTS (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 28,838
Fair Value, Recurring [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	28,817
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	28,817
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Agencies Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities
Fair Value, Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	3,598
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	3,598
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Fair Value, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details Narrative) $ in Thousands	Jun. 30, 2023 USD ($)
Fair Value Disclosures [Abstract]
Securities Borrowed, Fair Value Disclosure	$ 28,838

SCHEDULE OF MARKETABLE SECURITI

SCHEDULE OF MARKETABLE SECURITIES (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Marketable Securities [Line Items]
Marketable securities	$ 28,817
US Government Agencies Debt Securities [Member]
Marketable Securities [Line Items]
Marketable securities	$ 28,817

SCHEDULE OF FAIR VALUE OF MARKE

SCHEDULE OF FAIR VALUE OF MARKETABLE SECURITIES CLASSIFIED BY MATURITY (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Amounts maturing within one year	$ 17,429
Amounts maturing after one year through two years	11,388
Marketable securities	$ 28,817

SCHEDULE OF CHANGES IN FAIR VAL

SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Balance at beginning of the period
Additions	28,838
Sale or maturity
Changes in fair value during the period	(21)
Balance at end of the period	$ 28,817

SCHEDULE OF ISSUANCE OF WARRANT

SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Class of Stock [Line Items]
Total Warrants	53,449,832
Series E Warrants [Member]
Class of Stock [Line Items]
Total Warrants	198,159
Weighted average exercise price | $ / shares	$ 27
Series F Warrants [Member]
Class of Stock [Line Items]
Total Warrants	433,878
Weighted average exercise price | $ / shares	$ 7.4250
Series G Warrants [Member]
Class of Stock [Line Items]
Total Warrants	1,092,344
Weighted average exercise price | $ / shares	$ 10.230
Series H Warrants [Member]
Class of Stock [Line Items]
Total Warrants	12,914,086
Weighted average exercise price | $ / shares	$ 1.3827
Series I Warrants [Member]
Class of Stock [Line Items]
Total Warrants	12,914,078
Weighted average exercise price | $ / shares	$ 1.3827
Series J Warrants [Member]
Class of Stock [Line Items]
Total Warrants	12,914,086
Weighted average exercise price | $ / shares	$ 1.3827
Series K Warrants [Member]
Class of Stock [Line Items]
Total Warrants	12,914,078
Weighted average exercise price | $ / shares	$ 1.3827
Underwriter Warrants [Member]
Class of Stock [Line Items]
Total Warrants	17,966
Weighted average exercise price | $ / shares	$ 7.4250
Other Warrants [Member]
Class of Stock [Line Items]
Total Warrants	51,157
Weighted average exercise price, description	225 and above

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)						3 Months Ended	6 Months Ended
	Jul. 01, 2023	May 17, 2023	May 12, 2023	Apr. 01, 2023	Jan. 06, 2023	Jun. 30, 2023	Jun. 30, 2023	May 16, 2023	Dec. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding						53,449,832	53,449,832
Capital stock shares authorized						155,000,000	155,000,000
Capital stock par value						$ 0.0001	$ 0.0001
Common stock shares authorized						150,000,000	150,000,000		150,000,000
Director [Member]
Subsidiary, Sale of Stock [Line Items]
Accrual for director fees						$ 55,000,000	$ 55,000,000
Cash paid for fees						22,875,000
Value of common shares issued						$ 32,125
Director [Member] | Subsequent Event [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued	12,648
Restricted Stock [Member] | Employees And Directors [Member]
Subsidiary, Sale of Stock [Line Items]
Shares granted							2,569,540
Fair value of shares granted							$ 4,520,000
Restricted Stock [Member] | Chief Executive Officer [Member]
Subsidiary, Sale of Stock [Line Items]
Shares granted							1,045,150
Fair value of shares granted							$ 1,839,000
Share-Based Payment Arrangement, Option [Member] | Employees And Directors [Member]
Subsidiary, Sale of Stock [Line Items]
Options to purchase common stock		1,011,930
Stock option exercise price		$ 1.76
Expected dividend rate		0%
Expected volatility, minimum		116.76%
Expected volatility, maximum		123.30%
Fair value stock option price		$ 1,560,000
Risk-free interest rate, minimum		3.58%
Share-Based Payment Arrangement, Option [Member] | Employees And Directors [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Expected term		5 years 6 months
Share-Based Payment Arrangement, Option [Member] | Employees And Directors [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Expected term		6 years 6 months
Share-Based Payment Arrangement, Option [Member] | Consultants [Member]
Subsidiary, Sale of Stock [Line Items]
Options to purchase common stock		575,000			50,000
Stock option exercise price		$ 1.76			$ 1.15
Expected dividend rate		0%			0%
Expected volatility, minimum		116.76%			124.58%
Expected volatility, maximum		123.30%			125.61%
Risk-free interest rate, minimum		3.58%			3.65%
Risk-free interest rate, maximum					3.68%
Fair value stock option price		$ 885			$ 50,658
Share-Based Payment Arrangement, Option [Member] | Consultants [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Expected term		5 years 6 months			5 years 1 month 15 days
Share-Based Payment Arrangement, Option [Member] | Consultants [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Expected term		6 years 6 months			6 years 6 months
Share-Based Payment Arrangement, Option [Member] | Consultants [Member] | Three Year Vesting Period [Member]
Subsidiary, Sale of Stock [Line Items]
Options to purchase common stock					45,000
Share-Based Payment Arrangement, Option [Member] | Consultants [Member] | Vesting in First Year [Member]
Subsidiary, Sale of Stock [Line Items]
Options to purchase common stock					20,000
Share-Based Payment Arrangement, Option [Member] | Consultants [Member] | Vesting in Second Year [Member]
Subsidiary, Sale of Stock [Line Items]
Options to purchase common stock					15,000
Share-Based Payment Arrangement, Option [Member] | Consultants [Member] | Vesting in Third Year [Member]
Subsidiary, Sale of Stock [Line Items]
Options to purchase common stock					10,000
Share-Based Payment Arrangement, Option [Member] | Consultants [Member] | Performance Conditions [Member]
Subsidiary, Sale of Stock [Line Items]
Options to purchase common stock					5,000
Series C Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock conversion price			$ 1.3827
Preferred stock convertible shares issuable			5,668			7,952	7,952
Preferred stock outstanding						1,718	1,718	1,718	1,718
Preferred stock shares authorized						1,172,000	1,172,000		1,172,000
PreFunded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price			$ 0.0001
Warrants outstanding						15,561,894	15,561,894
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Offering price			1.6326
Warrant exercise price			$ 1.3827
Preferred Stock Blank Check [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock shares authorized						5,000,000	5,000,000
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering				29,746		10,266,270	10,266,270
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of issuance of public offering			10,266,270
Private placement			$ 42,200,000
Fees payable and other offering expenses			4,600,000
Warrant exercises			$ 71,400,000
Private Placement [Member] | PreFunded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding			15,561,894
Private Placement [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding			51,656,328
Offering price			$ 1.6327
Private Placement [Member] | Series H Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding			12,914,086
Private Placement [Member] | Series I Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding			12,914,078
Private Placement [Member] | Series J Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding			12,914,086
Private Placement [Member] | Series K Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding			12,914,078
At The Market Offering [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants outstanding						53,449,832	53,449,832

RELATED PARTIES TRANSACTIONS (D

RELATED PARTIES TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Director [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Marketing services from related party	$ 0	$ 2,500	$ 0	$ 8,776

NET LOSS PER SHARE (Details Nar

NET LOSS PER SHARE (Details Narrative) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average prefunded warrants	7,866,452		3,954,956
Diluted loss per share	75,186,979	3,010,707	75,186,979	3,010,707
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Diluted loss per share			2,905,615	547,792

SCHEDULE OF INVENTORIES (Detail

SCHEDULE OF INVENTORIES (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 177	$ 179
Work in process	513	510
Raw materials and supplies	999	932
Total inventory	$ 1,689	$ 1,621

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUALS - OTHER (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Employees and employee institutions	$ 1,263	$ 1,853
Accrued vacation and recreation pay	303	197
Accrued expenses	742	554
Clinical trial accrual	1,214	1,258
Current Operating lease liabilities	418	419
Other	121	130
Accounts Payable and Accruals - Other	$ 4,061	$ 4,411

SCHEDULE OF REVENUES ATTRIBUTED

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 1,649	$ 1,531	$ 2,888	$ 2,714
GERMANY
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	276	426	490	675
ITALY
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	338	229	605	473
Other Countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 1,035	$ 876	$ 1,793	$ 1,566

SCHEDULE OF REVENUES ATTRIBUT_2

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRODUCT (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue from External Customer [Line Items]
Revenue	$ 1,649	$ 1,531	$ 2,888	$ 2,714
CGuard EPS [Member]
Revenue from External Customer [Line Items]
Revenue	1,649	1,505	2,888	2,666
MGuard Prime EPS [Member]
Revenue from External Customer [Line Items]
Revenue		$ 26		$ 48

SCHEDULE OF REVENUES ATTRIBUT_3

SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS (Details) - Sales [Member] - Customer Concentration Risk [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Customer A [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues per major customer	17%	28%	17%	25%
Customer B [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues per major customer	11%	8%	12%	9%